KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) EBITDA (2016 - 2025)

Historic EBITDA for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to -$130.8 million.

  • CRISPR Therapeutics AG's EBITDA fell 18407.77% to -$130.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$578.6 million, marking a year-over-year decrease of 5795.21%. This contributed to the annual value of -$578.6 million for FY2025, which is 5795.21% down from last year.
  • According to the latest figures from Q4 2025, CRISPR Therapeutics AG's EBITDA is -$130.8 million, which was down 18407.77% from -$105.5 million recorded in Q3 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's EBITDA peaked at $759.1 million during Q2 2021, and registered a low of -$208.6 million during Q2 2025.
  • For the 5-year period, CRISPR Therapeutics AG's EBITDA averaged around -$68.5 million, with its median value being -$116.8 million (2021).
  • Per our database at Business Quant, CRISPR Therapeutics AG's EBITDA skyrocketed by 105288.29% in 2021 and then tumbled by 18407.77% in 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's EBITDA (Quarter) stood at -$145.5 million in 2021, then rose by 28.57% to -$104.0 million in 2022, then soared by 194.32% to $98.1 million in 2023, then plummeted by 146.95% to -$46.0 million in 2024, then crashed by 184.08% to -$130.8 million in 2025.
  • Its last three reported values are -$130.8 million in Q4 2025, -$105.5 million for Q3 2025, and -$208.6 million during Q2 2025.